Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| Mesothelin Lower in sarcomatoid | 85-100% | Epithelioid histology | Wikipedia |
| VISTA Expression on inflammatory cells in 94%; VISTA-high associated with better survival | 85% | IHC, any VISTA on tumour cells (TMA, n=319; 88% epithelioid, 90% biphasic, 42% sarcomatoid) | doi.org |
| PRMT5 (MTAP-deleted cancers) | 40% | MTAP homozygous deletion |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
5 cell lines, 1 mouse models and 4 repositories are listed for this cancer. See them →